Overview

Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease

Status:
Terminated

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

To demonstrate the superiority of donepezil over placebo in improving cognitive function, neuropsychiatric burden and functional ability in people with Parkinson's disease and mild dementia after 24 months of treatment. To demonstrate the superiority of donepezil over placebo in improving patient and carer quality of life and to establish the cost-effectiveness of donepezil. To determine the instrument most suitable for evaluating change in cognition in people with Parkinson's disease and mild dementia.

Phase:

Phase 3

Details

Lead Sponsor:

Newcastle-upon-Tyne Hospitals NHS Trust

Collaborators:

Bangor University
King's College London
Lancashire Care NHS Foundation Trust
London School of Economics and Political Science
Newcastle University
University College, London
University of Birmingham
University of Cambridge
University of Manchester
University of Newcastle Upon-Tyne

Treatments:

Cholinesterase Inhibitors
Donepezil